argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo

1 week ago 1
FDA Headquarters - White Oak Campus

hapabapa

  • argenx (NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
  • The agency says that the treatment, used for generalized myasthenia gravis

Recommended For You

More Trending News

Read Entire Article